论文部分内容阅读
目的 探讨尼莫地平注射液防治蛛网膜下腔出血 (SAH)后脑血管痉挛 (CVS)的疗效。方法 12 0例SAH病人随机分为治疗组 70例和对照组 5 0例 ,治疗组在与对照组相同的常规治疗基础上加用尼莫地平注射液 10mg/ 5 0ml,静脉滴注 ,然后改为尼莫地平片 3 0mg ,口服。 结果 治疗组CVS发生率、CVS持续时间、脑梗死 (CI)发生率、病死率均明显低于对照组 ,CVS治愈率明显高于对照组 ,而再出血发生率无明显差异。结论 尼莫地平防治SAH后CVS疗效显著且无增加再出血的危险
Objective To investigate the efficacy of nimodipine injection in preventing cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH). Methods A total of 120 SAH patients were randomly divided into treatment group (n = 70) and control group (n = 50). The treatment group was given nimodipine injection 10mg / 50ml on the basis of the same routine treatment as the control group, Nimodipine tablets 30mg, orally. Results The incidence of CVS, the duration of CVS, the incidence of cerebral infarction (CI) and the mortality in the treatment group were significantly lower than those in the control group. The cure rate of CVS was significantly higher than that of the control group, while there was no significant difference in the incidence of rebleeding. Conclusion The efficacy of CVS after nimodipine in preventing and treating SAH is significant and there is no risk of rebleeding